Aktienanalyse zu Mirum Pharmaceuticals Inc (MIRM)MIRMMirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Mirum Pharmaceuticals is currently a hold. The stock's current price is $97.46, and while it has shown a year-to-date increase of 24.84%, the RSI is at 40.814, indicating potential weakness. The forward P/E ratio is at 39.68, suggesting it may be overvalued given the recent earnings miss and regulatory hurdles. The main risk is the FDA's requirement for an additional Phase 3 study, which may delay the drug's market entry, creating uncertainty.